Neuro Imaging Clinical Trials
MR Fingerprinting: A Novel Sequence Applied to Neuroimaging (PI: Yueh Lee)
Purpose: The purpose of this study is to evaluate novel quantitative MRI techniques in clinical studies to determine whether they can provide better, faster and more useful information for clinical diagnosis. In this study, we propose to apply MR Fingerprinting at UNC and evaluate its performance for different neurological diseases. We hypothesis that the quantitative MR imaging technique will lead to improved tissue characterization and diagnosis.
Participants: Approximately 100 patients at UNC that receive a neurological MRI will be recruited.
Procedures (methods): A novel neuro MR technique less than 15 minutes will be added to the standard MRI sequence here at UNC.
Assessment of Novel Neuroradiological MRI Sequences (PI: Yueh Lee)
Purpose: The purpose of this study is to evaluate new computer programs for Magnetic Reasoning Imaging (MRI) for neurological studies.
Participants: One hundred (100) subjects who are being studied with clinically indicated neurological MRIs.
Procedures (methods): Patients will be consented to undergo novel neurological MRI sequences in addition to their clinical sequences.
EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma (PI: Yueh Lee)
Purpose: To determine whether binary changes (increase vs. decrease) in normalized rCBV within enhancing tumor from baseline to 2 weeks after initiation of anti-angiogenic therapy is associated with overall survival (OS).
Participants: The accrual for the trial is 165 participants over 24 months. We will enroll approximately 10 at UNC.
Procedures (methods): Patients with histologically proven GBM or gliosarcoma are identified by the local site to have progressed by RANO criteria. Patients scheduled to undergo bevacizumb therapy will have a baseline DSC-MRI prior to bevacizumab initiation and then will have a second DSC-MRI approximately 15 days after initiation. All patients will be followed for a minimum of 1 year and up to 5 years. Follow-up on all patients will continue until the last patient’s 1-year follow-up is completed.